top of page

Pre-Launch Phase: Large Pharmaceutical Company (Oncology)


Situation: A large pharmaceutical company had completed pivotal clinical trials for a breakthrough immuno-oncology drug demonstrating significant tumor shrinkage and improved patient survival rates.


  • Challenges:

  • Ensuring timely publication of positive clinical trial data in high-impact oncology journals to maximize pre-launch visibility and scientific credibility.

  • Identifying the most appropriate journals for each data set, considering readership, impact factor, and specific focus within the field of immuno-oncology.

  • Collaborating with internal medical writers to ensure accurate and compelling presentation of the clinical trial data, adhering to journal submission guidelines.


  • Impact:

  • Developed a strategic publication plan, prioritizing journals based on their audience reach and relevance to the specific type of cancer targeted by the drug.

  • Worked closely with internal medical writers to develop well-structured manuscripts that effectively showcased the drug's efficacy and safety profile.

  • Proactively addressed any reviewer inquiries or concerns to ensure smooth publication processes and minimize delays.

  • Secured publication of pivotal trial data in top-tier oncology journals, generating significant pre-launch buzz and excitement among oncologists.


  • Results: The well-defined publication strategy secured the publication of pivotal trial data in top oncology journals, maximizing visibility and scientific credibility. This generated significant pre-launch interest and excitement among oncologists for the new breakthrough drug.

Comentarios


bottom of page